Research programme: antibacterials - Basilea Pharmaceutica

Drug Profile

Research programme: antibacterials - Basilea Pharmaceutica

Alternative Names: BAL 19764; BAL 29880; BAL0019764; BAL0029641; BAL0030205; BAL2057; BAL30376; HKI9924109

Latest Information Update: 26 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Basilea Pharmaceutica
  • Class Macrolides; Monobactams
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Acne; Gram-negative infections; Gram-positive infections; Rosacea

Most Recent Events

  • 18 May 2009 Antimicrobial data from in vitro studies in Bacterial infections presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2009)
  • 28 Oct 2008 Antimicrobial data from in vitro studies in Bacterial infections presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,
  • 22 Apr 2008 Antimicrobial and pharmacodynamics data from a preclinical trial in Bacterial infections presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top